<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431495</url>
  </required_header>
  <id_info>
    <org_study_id>CAPP-study</org_study_id>
    <nct_id>NCT01431495</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)</brief_title>
  <acronym>(CAPP)</acronym>
  <official_title>Clinical Assessment of Pidogrel® Versus Plavix®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients
      with coronary disease:

        -  Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg
           loading dose or after the last maintenance dose (75 mg).

        -  Secondary Outcome Measures: Time to first occurrence of major cardio-vascular events
           (MACE).

        -  Safety Criteria: severe bleeding (GUSTO scale).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      after randomization of patients in both groups (Plavix or Pidogrel), the measure of platelet
      activity by the VerifyNow assay, 4 to 12 hours after the loading dose of 600mg or after the
      last dose of clopidogrel for patients on maintenance dose. The VerifyNow assay will
      determine: - The PRU:-P2Y12 Reaction Units-

      -% Of platelet inhibition It will be considered low responder or clopidogrel resistant
      patient with PRU&gt; 235 or %inhibition &lt;15%.

      Monitoring of patients included in the study will take place over a period of 12 months, MACE
      will be notified and dated. MACE criteria are: angina, myocardial infarction, coronary
      angioplasty, coronary artery bypass graft, and stroke.

      Each hemorrhagic event will be notified and classified according to the GUSTO scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- study the respective effects of Pidogrel ® and Plavix ® on platelet aggregation through the test VerifyNow ® - Time to first occurrence of post-randomization major adverse cardiac events (MACE)</measure>
    <time_frame>06 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>plavix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient treated by the princeps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient treated by Pidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pidogrel</intervention_name>
    <description>Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.</description>
    <arm_group_label>Pidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plavix</intervention_name>
    <description>Plavix(R) 75 mg/day for period ranging from 1 to 6 months.</description>
    <arm_group_label>plavix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female,

          -  Old (e) over 20 years

          -  Patients hospitalized for acute coronary syndrome (Whatever the T and troponin)

          -  Patients with proven coronary candidates for treatment with clopidogrel (who received
             a loading dose of 600mg over 2 hours and treated with 75mg / d of clopidogrel for
             longer than 7 days)

        Exclusion Criteria:

          -  Patients unwilling.

          -  Patient participating in another study.

          -  Patients with cardiogenic shock

          -  Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability

          -  Patients scheduled for surgery in less than 6 months.

          -  Patients candidates for coronary angioplasty

          -  Patients who underwent TAC + / - bare stent fewer than 30 days.

          -  Patients who underwent stenting with ATC active there is less than 12 months.

          -  ischemic stroke older than 6 weeks.

          -  History of hemorrhagic stroke (any time)

          -  Patients on warfarin or candidates

          -  Patients with a different anti ADP (ticlopidine, prasugrel)

          -  Patients with indication for clopidogrel-cons (side effects, bleeding ...)

          -  Thrombocytopenia &lt;100000/mm3

          -  anemia (Ht &lt;30%)

          -  Thrombocythaemia (Ht&gt; 52%)

          -  Patients seeking treatment for an elective forms of Clopidogrel.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachid MECHMECHE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>hospital La RABTA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>cardiology department, hospital La RABTA</name>
      <address>
        <city>Tunis</city>
        <state>Tunis BAB SOUIKA</state>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <last_update_submitted>September 8, 2011</last_update_submitted>
  <last_update_submitted_qc>September 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet agregation</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>major adverse cardiac events (MACE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

